PharmaCorp Rx Past Earnings Performance
Past criteria checks 0/6
PharmaCorp Rx's earnings have been declining at an average annual rate of -723.9%, while the Consumer Retailing industry saw earnings growing at 6.5% annually.
Key information
-723.9%
Earnings growth rate
-72.9%
EPS growth rate
| Consumer Retailing Industry Growth | 10.3% |
| Revenue growth rate | n/a |
| Return on equity | -4.9% |
| Net Margin | -382.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How PharmaCorp Rx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -1 | 1 | 0 |
| 31 Mar 24 | 0 | -1 | 1 | 0 |
| 31 Dec 23 | 0 | 0 | 1 | 0 |
| 30 Sep 23 | 0 | 0 | 0 | 0 |
| 30 Jun 23 | 0 | 0 | 0 | 0 |
| 31 Mar 23 | 0 | -1 | 1 | 0 |
| 31 Dec 22 | 0 | -1 | 1 | 0 |
| 30 Sep 22 | 0 | -1 | 1 | 0 |
Quality Earnings: PCRX is currently unprofitable.
Growing Profit Margin: PCRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PCRX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PCRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PCRX is unprofitable, making it difficult to compare its past year earnings growth to the Consumer Retailing industry (-11.7%).
Return on Equity
High ROE: PCRX has a negative Return on Equity (-4.93%), as it is currently unprofitable.